Date: 2015-04-28
Type of information: Nomination
Compound:
Company: RegenXBio (USA - MD)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 28, 2015, RegenXBio, a leading biotechnology company in gene therapy, announced that Luke M. Beshar has been appointed to its board of directors effective April 15. Mr. Beshar will serve as the chairman of RegenXBio’s audit committee. Mr. Beshar brings more than 35 years of leadership experience to RegenXBio’s board. Most recently, he was Executive Vice President and Chief Financial Officer at NPS Pharmaceuticals, Inc. Mr. Beshar helped reposition NPS as a leading global rare disease biopharmaceutical company, and was a key member of the team that led a $5.2 billion sale to Shire plc in February 2015. Prior to NPS, Mr. Beshar served in leadership positions and as chief financial officer for numerous organizations including Cambrex Corporation, Dendrite International, Expanets, Inc., PNY Technologies, Inc., WSR Corporation, The Genlyte Group, Inc., Bairnco Corporation and Arthur Andersen & Co.
Financial terms:
Latest news:
